James Basta - 01 Mar 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, General Counsel
Signature: James Basta
Issuer symbol: NTLA
Transactions as of: 01 Mar 2026
Net transactions value: -$16,688
Form type: 4
Filing time: 03 Mar 2026, 16:18:31 UTC
Previous filing: 07 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
BASTA JAMES	EVP, General Counsel	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE	James Basta	03 Mar 2026	0001792726

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+46,080	+41%	$0.000000	158,005	01 Mar 2026	Direct	F1
transaction	NTLA	Common Stock	Sale	$16,688	-1,211	-0.77%	$13.78	156,794	02 Mar 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Award	$0	+65,829		$0.000000	65,829	01 Mar 2026	Common Stock	65,829	$13.78	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit
F2	Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person.
F3	This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.